GYREGyre Therapeutics, Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -99% · now 24% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can GYRE take a bad year?
The deepest fall in GYRE's price history on file is −99%; it is 24% below its high today.
Worst drawdown on file · −24% today
- Cash runway
- 5+ years
Cash runway · burning $1.5M a quarter at the current rate
- Annualised volatility
- 76%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $57M
- EBITDA, trailing twelve months
- −$14M
- Operating profit, trailing twelve months
- −$17M
- Annualised volatilitytwo years of daily moves
- 76%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 24%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.